Literature DB >> 6660630

Activity of flubendazole against developing stages of Dirofilaria immitis in dogs.

J Guerrero, B P Campbell Seibert, K M Newcomb, B F Michael, J W McCall.   

Abstract

A formulation of flubendazole was studied to determine the activity against developing stages of Dirofilaria immitis in artificially infected pups. Flubendazole suspension was administered subcutaneously at a dose rate of 50 mg/kg of body weight once a day for 1, 3, or 5 consecutive days at various times during the experimental period. The pups were necropsied 6 months after the experimental infection, and the heart and pulmonary arteries were examined for adult worms. Optimal activity was obtained when flubendazole suspension was administered subcutaneously for 5 consecutive days, either 1 or 2 months after infection. The formation of encapsulated deposits, containing white viscous fluid, was observed at the injection sites of all treated pups.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6660630

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Investigating Flubendazole as an Anthelmintic Treatment for Guinea Worm (Dracunculus medinensis): Clinical Trials in Laboratory-Reared Ferrets and Domestic Dogs in Chad.

Authors:  Christopher A Cleveland; Kayla B Garrett; Erin K Box; Alec T Thompson; Ellen K Haynes; Deborah L Elder; Robert L Richards; Ania A Majewska; Sarah Anne J Guagliardo; Ryan E Wiegand; John A Bryan Ii; Fernando Torres-Velez; Karmen Unterwegner; Mario Romero; Hubert Zirimwabagabo; Metinou Sidouin; Philip Tchindebet Oaukou; Mbang Mahammat Ada; Bongo Nare Richard Ngandolo; Charles D Mackenzie; Timothy G Geary; Adam J Weiss; Michael J Yabsley
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

2.  The genome of the heartworm, Dirofilaria immitis, reveals drug and vaccine targets.

Authors:  Christelle Godel; Sujai Kumar; Georgios Koutsovoulos; Philipp Ludin; Daniel Nilsson; Francesco Comandatore; Nicola Wrobel; Marian Thompson; Christoph D Schmid; Susumu Goto; Frédéric Bringaud; Adrian Wolstenholme; Claudio Bandi; Christian Epe; Ronald Kaminsky; Mark Blaxter; Pascal Mäser
Journal:  FASEB J       Date:  2012-08-13       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.